From "made in China" to "defined by China": can NewCo lead the way | Part 1

The blueprint is clear. Chinese biotech is going global with NewCo — and it's working.

In 2024 alone, NewCo deals unlocked $3.8B in upfront payments for Chinese innovators, surpassing IPOs as the go-to path for global expansion.

What's the secret behind its power? Dive into the 5 core advantages in our latest VBtalk video 👇

Watch the previous video: China's biopharma goes global: innovative drug NewCo partnership case